Ultra-early tirofiban after failed tenecteplase in branch atheromatous disease: efficacy and safety

Abstract

Branch atheromatous disease (BAD), a common acute ischemic stroke subtype with high progression and recurrence risk, often shows limited improvement following intravenous thrombolysis. The glycoprotein IIb/IIIa antagonist tirofiban combined with tenecteplase (TNK) may enhance recanalization. This multicenter retrospective analysis included 1025 patients with BAD who completed intravenous TNK thrombolysis without symptomatic relief between September 2022 and 2025. Patients were assigned to tirofiban ( n = 309) or control ( n = 716) groups, according to ultra-early tirofiban administration. In the primary IPTW-weighted analysis, ultra-early tirofiban administration was significantly associated with a higher proportion of patients achieving 90-day modified Rankin Scale (mRS) ≤ 1( 63.4% vs. 42.7%; IPTW-weighted OR = 2.44, 95% CI: 1.82–3.28, P < 0.001) and mRS ≤ 2 (71.8% vs. 57.7%; IPTW-weighted OR = 2.00, 95% CI: 1.47–2.72, P < 0.001). Supportive sensitivity analyses using propensity score matching (256 pairs) yielded consistent findings (mRS ≤ 1: 62.5% vs. 44.5%, aOR: 1.404, 95% CI: 1.104–1.785, P = 0.006). Regarding safety endpoints, symptomatic intracranial hemorrhage (sICH) occurred in five (1.6%) tirofiban-treated and three (0.4%) control patients in the IPTW analysis (IPTW-weighted OR = 5.06, 95% CI: 0.64–40.19, P = 0.125), and 90-day mortality was 2.9% vs. 2.0% (IPTW-weighted OR = 1.65, 95% CI: 0.68–4.00, P = 0.263). Although no statistically significant differences were observed, the low number of safety events results in wide confidence intervals; thus, the safety of ultra-early tirofiban cannot be definitively established based on the current analysis, and an increased risk of sICH cannot be excluded.

Efficacy of teprotumumab N01 (IBI311), an IGF-1R inhibitor, for thyroid eye disease patients who had failed glucocorticoids
Wei Zhao, Tian-Yuan Li, Ying Na +6
International Journal of Ophthalmology2 Nov 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicinePMC
Efficacy and Safety of Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Fariba Asadi, Zahra Amouzeshi, Hassan Eslami Aliabadi
Iranian Journal of Child Neurology1 Sep 2026Peer-reviewedCC BY-NC 4.0Full textEpidemiology & public healthPMC
Floating Atheromatous Plaque in the Common Femoral Artery: A Rare Case With Implications for Diagnosis and Management.
Julian M Paione Oleszuk, Mohammad Ghasemi, Jens Achenbach +2
Cureus8 Oct 2026Peer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
The comparison of short-term outcome between tenecteplase and alteplase in minor acute ischemic stroke based on neutrophil-to-lymphocyte ratio stratification
Liangxu Xiang, Jing Xu, Zhaohai Feng +6
Scientific Reports4 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthCrossref
Intra-Arterial Tenecteplase After Endovascular Thrombectomy for Acute Stroke
Xin Tong, Jin Bai, Gang Luo +30
JAMA28 Sep 2026Peer-reviewedLicence not statedFull textEpidemiology & public healthPMC

Cite

BibTeX RIS

BibTeX

@article{li2026ultraearly,
  title = {{Ultra-early tirofiban after failed tenecteplase in branch atheromatous disease: efficacy and safety}},
  author = {Jiarong Li and Lili Zhu and Ying Zhang and Yang Yang and Shaolei Zhang and Lijuan Liu and Xiaofei Gao and Weifeng Chen and Liang Song and Shengqi Fu},
  journal = {Scientific Reports},
  year = {2026},
  month = oct,
  doi = {10.1038/s41598-026-76421-z},
  url = {https://www.nature.com/articles/s41598-026-76421-z},
  note = {CC BY 4.0},
}

RIS

TY  - JOUR
TI  - Ultra-early tirofiban after failed tenecteplase in branch atheromatous disease: efficacy and safety
AU  - Jiarong Li
AU  - Lili Zhu
AU  - Ying Zhang
AU  - Yang Yang
AU  - Shaolei Zhang
AU  - Lijuan Liu
AU  - Xiaofei Gao
AU  - Weifeng Chen
AU  - Liang Song
AU  - Shengqi Fu
PY  - 2026
DA  - 2026/10/23
JO  - Scientific Reports
DO  - 10.1038/s41598-026-76421-z
UR  - https://www.nature.com/articles/s41598-026-76421-z
AB  - Branch atheromatous disease (BAD), a common acute ischemic stroke subtype with high progression and recurrence risk, often shows limited improvement following intravenous thrombolysis. The glycoprotein IIb/IIIa antagonist tirofiban combined with tenecteplase (TNK) may enhance recanalization. This multicenter retrospective analysis included 1025 patients with BAD who completed intravenous TNK thrombolysis without symptomatic relief between September 2022 and 2025. Patients were assigned to tirofiban ( n = 309) or control ( n = 716) groups, according to ultra-early tirofiban administration. In the primary IPTW-weighted analysis, ultra-early tirofiban administration was significantly associated with a higher proportion of patients achieving 90-day modified Rankin Scale (mRS) ≤ 1( 63.4% vs. 42.7%; IPTW-weighted OR = 2.44, 95% CI: 1.82–3.28, P < 0.001) and mRS ≤ 2 (71.8% vs. 57.7%; IPTW-weighted OR = 2.00, 95% CI: 1.47–2.72, P < 0.001). Supportive sensitivity analyses using propensity score matching (256 pairs) yielded consistent findings (mRS ≤ 1: 62.5% vs. 44.5%, aOR: 1.404, 95% CI: 1.104–1.785, P = 0.006). Regarding safety endpoints, symptomatic intracranial hemorrhage (sICH) occurred in five (1.6%) tirofiban-treated and three (0.4%) control patients in the IPTW analysis (IPTW-weighted OR = 5.06, 95% CI: 0.64–40.19, P = 0.125), and 90-day mortality was 2.9% vs. 2.0% (IPTW-weighted OR = 1.65, 95% CI: 0.68–4.00, P = 0.263). Although no statistically significant differences were observed, the low number of safety events results in wide confidence intervals; thus, the safety of ultra-early tirofiban cannot be definitively established based on the current analysis, and an increased risk of sICH cannot be excluded.
SN  - 2045-2322
ER  -

Abstract

Related

Cite